MT Newswires Live09-04 19:33
United Laboratories International (HKG:3933) unit The United Bio-Technology (Hengqing) dosed the first participant in a phase III clinical trial of UBT251 Injection in China, according to a Hong Kong bourse filing on Friday.
The study aims to evaluate the efficacy and safety of the drug in overweight participants or those with obesity.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.
